Kapitel 60: Lungenkarzinom


Cox JD, Azarnia N, Byhardt RW et al. (1990) A randomized phase III trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.3 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 9: 1543–1555


Douillard JY, Rosell R, Delena M et al. (2005) ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (Stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. ASCO #7013


Horsowitz JM, Park S, Bogenmann E et al. (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87: 2775–2779


